SELLAS Life Sciences Group, Inc. (NASDAQ:SLS – Get Free Report) CFO John Thomas Burns sold 3,831 shares of the business’s stock in a transaction dated Wednesday, November 18th. The shares were sold at an average price of $19.18, for a total value of $73,478.58. Following the transaction, the chief financial officer owned 558,893 shares in the company, valued at $10,719,567.74. This represents a 0.68% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
SELLAS Life Sciences Group Trading Down 8.1%
SELLAS Life Sciences Group stock traded down $1.20 during trading hours on Friday, hitting $13.66. The stock had a trading volume of 15,361,567 shares, compared to its average volume of 7,646,582. The company has a 50-day moving average of $11.11 and a two-hundred day moving average of $8.99. SELLAS Life Sciences Group, Inc. has a fifty-two week low of $1.39 and a fifty-two week high of $24.89.
SELLAS Life Sciences Group (NASDAQ:SLS – Get Free Report) last announced its quarterly earnings data on Thursday, November 12th. The company reported ($0.05) EPS for the quarter, hitting analysts’ consensus estimates of ($0.05).
Institutional Trading of SELLAS Life Sciences Group
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Nykredit A S bought a new position in SELLAS Life Sciences Group during the second quarter worth about $27,000. GAMMA Investing LLC boosted its holdings in SELLAS Life Sciences Group by 293.2% during the third quarter. GAMMA Investing LLC now owns 2,186 shares of the company’s stock valued at $27,000 after purchasing an additional 1,630 shares in the last quarter. Robinhood Markets Inc. bought a new stake in shares of SELLAS Life Sciences Group in the 3rd quarter valued at approximately $33,000. Allworth Financial LP grew its stake in shares of SELLAS Life Sciences Group by 1,107.2% in the 3rd quarter. Allworth Financial LP now owns 5,698 shares of the company’s stock valued at $70,000 after purchasing an additional 5,226 shares during the period. Finally, Sterling Capital Management LLC grew its stake in shares of SELLAS Life Sciences Group by 900.8% in the 3rd quarter. Sterling Capital Management LLC now owns 6,635 shares of the company’s stock valued at $82,000 after purchasing an additional 5,972 shares during the period. Institutional investors own 17.38% of the company’s stock.
Latest SELLAS Life Sciences Group News
Investors following SLS have been watching these news items:
- Neutral Sentiment: A Seeking Alpha article upgraded its rating after describing a “big win,” while noting areas of uncertainty. The headline provided does not specify the underlying development, limiting what can be concluded about its likely effect on the shares. Seeking Alpha article
- Neutral Sentiment: A report says a recent filing has prompted speculation among retail investors that SELLAS may have greater buyout leverage. That is an investor interpretation, not a confirmed acquisition process or offer. MSN report on the offering and buyout speculation
- Negative Sentiment: The $13 offering price and issuance of millions of new shares increase dilution risk for current shareholders. The discounted financing triggered a sharp selloff, outweighing the benefit of the added cash in the near term. StreetInsider offering report
Analysts Set New Price Targets
Several brokerages recently commented on SLS. Alliance Global Partners reaffirmed a “buy” rating on shares of SELLAS Life Sciences Group in a research report on Wednesday, August 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a research note on Thursday, October 15th. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, SELLAS Life Sciences Group currently has an average rating of “Hold” and an average price target of $10.00.
Read Our Latest Report on SELLAS Life Sciences Group
About SELLAS Life Sciences Group
SELLAS Life Sciences Group is a clinical-stage biopharmaceutical company focused on developing treatments for cancer. Its research centers on immunotherapies and other therapies intended to address hematologic malignancies and solid tumors. The company does not have an established portfolio of marketed products; its work is focused on clinical development. Its pipeline includes galinpepimut-S (GPS), an immunotherapy designed to target the Wilms’ tumor 1 (WT1) protein, which is found in several types of cancer.
Read More
- Five stocks we like better than SELLAS Life Sciences Group
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for SELLAS Life Sciences Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SELLAS Life Sciences Group and related companies with MarketBeat.com's FREE daily email newsletter.
